ROS-Mediated Disruption of the Cell Cycle and Mitochondrial Function by CGF in Colorectal Cancer

Study Background and Research Question

Colorectal cancer (CRC) is a leading cause of cancer-related mortality, accounting for the third highest incidence and the second highest number of cancer deaths globally. Despite advances in surgery and adjuvant therapies, recurrence and metastasis remain major challenges, particularly for patients diagnosed at advanced stages. The need for novel, effective treatments has prompted exploration of natural products, which often exhibit multi-targeted bioactivity and favorable safety profiles. The reference study by Jiang et al. (iScience, 2026) investigates Cya-Gly-Fer (CGF), an anthocyanin derivative extracted from purple sweet potato tubers, focusing on its antitumor potential in CRC models and the underlying molecular mechanisms.

Key Innovation from the Reference Study

The central innovation lies in demonstrating that CGF suppresses CRC progression through a distinct mechanism involving excessive reactive oxygen species (ROS) production, targeted metabolic reprogramming, and mitochondrial dysfunction. Unlike conventional chemotherapeutics that target cell division machinery directly, CGF disrupts cellular energy homeostasis and redox balance, ultimately leading to cell cycle arrest and apoptosis. Notably, the study elucidates the sequence of signaling events: CGF-mediated downregulation of ATP-binding cassette (ABC) transporters causes intracellular ATP accumulation, which impairs mitochondrial function, triggers ROS overload, and suppresses the oncogenic MAPK/ERK/c-MYC axis. These interconnected disruptions provide a unified mechanistic explanation for CGF's antitumor efficacy.

Methods and Experimental Design Insights

The researchers employed a multi-tiered approach combining in vitro, ex vivo, and in vivo models:

• Cellular models: Human CRC cell lines were treated with CGF to assess effects on proliferation, cell cycle distribution, apoptosis, and metabolic status.
• 3D organoids and xenograft models: These systems enabled the evaluation of CGF's efficacy in more physiologically relevant settings, including tumor growth inhibition and metastasis suppression.
• Omics integration: Transcriptomic and metabolomic profiling provided global insights into CGF-induced metabolic shifts, especially regarding central carbon metabolism and oxidative phosphorylation.
• Cell cycle and apoptosis analysis: The study utilized flow cytometry-based assays to dissect CGF-induced shifts in the distribution of cell cycle phases (G0/G1, S, G2/M) and to quantify apoptosis via sub-G1 peak detection—an approach conceptually aligned with protocols detailed in advanced cell cycle progression analysis guides such as internal resource.

Protocol Parameters

• CGF treatment concentration: Dose-ranging studies were performed, with most in vitro assays using micromolar concentrations (typically 10–50 μM) to evaluate dose-response relationships.
• ROS measurement: Intracellular ROS was quantified using fluorescent probes (such as DCFH-DA), allowing detection of oxidative stress post-CGF exposure.
• Flow cytometry cell cycle assay: Cells were fixed, treated with propidium iodide (PI) and RNase A, and analyzed for DNA content to differentiate G0/G1, S, and G2/M phases, as well as the sub-G1 apoptotic population.
• In vivo dosing: For xenograft models, CGF was administered at doses ensuring favorable pharmacokinetics and safety, with tumor volume and metastatic burden monitored over time.

Core Findings and Why They Matter

Key findings from the study (Jiang et al., 2026) include:

• Tumor growth and metastasis inhibition: CGF significantly inhibited CRC proliferation and metastatic spread in cell culture, organoid, and animal models.
• Metabolic reprogramming: CGF disrupted central carbon metabolism and oxidative phosphorylation, leading to ATP accumulation and mitochondrial dysfunction.
• ROS-mediated signaling suppression: The resulting ROS overload inhibited the MAPK/ERK/c-MYC axis, a pathway critical for cell growth and survival.
• Cell cycle arrest and apoptosis induction: Flow cytometry revealed increased accumulation of cells in the G0/G1 phase and a marked rise in the sub-G1 population, indicative of apoptosis driven by DNA fragmentation. This aligns with the critical role of apoptosis detection by sub-G1 peak in mechanistic oncology research.
• Safety and pharmacokinetics: CGF exhibited a favorable safety profile and pharmacokinetics in preclinical models, supporting its candidacy for further therapeutic development.

These findings are significant because they establish a mechanistic link between metabolic stress, redox imbalance, and cell cycle disruption. By targeting mitochondrial homeostasis, CGF circumvents some resistance mechanisms associated with traditional chemotherapies, suggesting translational potential for CRC treatment, especially in cases refractory to standard care.

Comparison with Existing Internal Articles

Internal articles such as "Cell Cycle Assay Kit: Advanced Analysis of Cell Cycle Phases" and "Precision Analysis of G0/G1, S, and G2/M Phases" emphasize the importance of robust, reproducible DNA content analysis in cell cycle research. The reference study's approach—combining PI/RNase A staining with flow cytometry for precise discrimination of cell cycle phases and apoptotic cells—mirrors best practices outlined in these guides. Moreover, the mechanistic insight into how metabolic and mitochondrial perturbations translate to detectable shifts in cell cycle progression underscores the value of integrating cell cycle and apoptosis detection into translational cancer research workflows, as described in thought-leadership resources on mechanistic oncology.

Limitations and Transferability

While the study provides compelling preclinical evidence, several limitations must be acknowledged:

• Lack of clinical data: All results derive from cell lines, organoids, and animal models; human clinical efficacy and safety remain to be established.
• Specificity of the mechanism: The effects of CGF on non-cancerous tissues and in other cancer types have not been fully explored, which may affect its broader applicability.
• Complexity of metabolic reprogramming: Although omics profiling identified key metabolic nodes, the full spectrum of downstream effects and potential compensatory mechanisms warrants further investigation.

Despite these caveats, the mechanistic insights and workflow examples provided are highly transferable to broader studies of cell cycle regulation, apoptosis, and metabolic therapeutics in oncology.

Research Support Resources

For researchers aiming to replicate or extend the findings of Jiang et al., accurate detection of cell cycle phases and apoptosis is essential. The Cell Cycle Assay Kit (Catalog No. K2263) (SKU K2263) from APExBIO offers validated PI and RNase A staining reagents and a streamlined protocol for flow cytometry-based analysis of G0/G1, S, and G2/M phases and sub-G1 apoptotic populations. This kit can support workflows involving cell cycle progression analysis and apoptosis detection by sub-G1 peak, as highlighted in both the reference study and internal methodological guides. Proper implementation of such assays enhances data reproducibility and mechanistic interpretation in cancer research.